Abstract
Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action. The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors. The evidence for and against the claim that broader spectrum agents are more efficacious is discussed. Examples of triple reuptake inhibitors in development are compared, and preclinical and clinical research with these agents to date is described.
Keywords: serotonin, antidepressants, neurotransmitters, inhibitors, clinical research, Triple-Action Hypothesis
Current Neuropharmacology
Title: Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Volume: 6 Issue: 4
Author(s): David M. Marks, Chi-Un Pae and Ashwin A. Patkar
Affiliation:
Keywords: serotonin, antidepressants, neurotransmitters, inhibitors, clinical research, Triple-Action Hypothesis
Abstract: Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action. The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors. The evidence for and against the claim that broader spectrum agents are more efficacious is discussed. Examples of triple reuptake inhibitors in development are compared, and preclinical and clinical research with these agents to date is described.
Export Options
About this article
Cite this article as:
Marks M. David, Pae Chi-Un and Patkar A. Ashwin, Triple Reuptake Inhibitors: The Next Generation of Antidepressants, Current Neuropharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157015908787386078
DOI https://dx.doi.org/10.2174/157015908787386078 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology Vascular effects of flavonoids
Current Medicinal Chemistry New Perspectives on the Structure and Function of the Na+ Channel Multigene Family
Current Medicinal Chemistry - Central Nervous System Agents Combination Therapeutic Approach for Asthma and Allergic Rhinitis
Current Clinical Pharmacology Efficacy and Complications of Subcutaneous <i>versus</i> Conventional Cardioverter Defibrillators: A Systematic Review and Meta-analysis
Current Cardiology Reviews Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update
Coronaviruses Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Blockade of Jagged/Notch Pathway Abrogates Transforming Growth Factor β2-Induced Epithelial-Mesenchymal Transition in Human Retinal Pigment Epithelium Cells
Current Molecular Medicine Mathematical Modeling of the Cancer Cell ’ s Control Circuitry: Paving the Way to Individualized Therapeutic Strategies
Current Signal Transduction Therapy Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA
Current Pharmaceutical Design Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry ω-3 Polyunsaturated Fatty Acids Effects on the Cardiometabolic Syndrome and their Role in Cardiovascular Disease Prevention: An Update from the Recent Literature
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Immunomodulatory Effects of <i>Allium sativum</i> L. and its Constituents against Viral Infections and Metabolic Diseases
Current Topics in Medicinal Chemistry Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes
CNS & Neurological Disorders - Drug Targets Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Current Pharmaceutical Design Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery